awmsg logo



midazolam (Buccolam®)


Reference No. 1046

Publication date:
19/06/2012


Appraisal information

midazolam (Buccolam®) oromucosal solution


Company: Shire Pharmaceuticals Ltd
BNF category: Central nervous system
NMG meeting date: 28/03/2012
AWMSG meeting date: 09/05/2012
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0912
Ministerial ratification: 19/06/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Midazolam (BUCCOLAM®) is recommended as an option for use within NHS Wales for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). For infants between 3–6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available. Midazolam (BUCCOLAM®) should be prescribed by brand name to reduce the risk of medication errors.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download